Search

Your search keyword '"Hogarty, Michael D"' showing total 482 results
Start Over Author "Hogarty, Michael D"
482 results on '"Hogarty, Michael D"'

1. Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial

Author

Hogarty, Michael D., Ziegler, David S., Franson, Andrea, Chi, Yueh-Yun, Tsao-Wei, Denice, Liu, Kangning, Vemu, Rohan, Gerner, Eugene W., Bruckheimer, Elizabeth, Shamirian, Anasheh, Hasenauer, Beth, Balis, Frank M., Groshen, Susan, Norris, Murray D., Haber, Michelle, Park, Julie R., Matthay, Katherine K., and Marachelian, Araz

Published
2024
Full Text
View/download PDF

2. Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531

Author

Brown, Erin G., Adkins, E. Stanton, Mattei, Peter, Hoffer, Fredric A., Wootton-Gorges, Sandra L., London, Wendy B., Naranjo, Arlene, Schmidt, Mary L., Hogarty, Michael D., Irwin, Meredith S., Cohn, Susan L., Park, Julie R., Maris, John M., Bagatell, Rochelle, Twist, Clare J., Nuchtern, Jed G., Davidoff, Andrew M., Newman, Erika A., and Lal, Dave R.

Published
2025
Full Text
View/download PDF

4. Epigenetic state determines inflammatory sensing in neuroblastoma

Author

Wolpaw, Adam J., Grossmann, Liron D., Dessau, Jessica L., Dong, May M., Aaron, Bailey J., Brafford, Patricia A., Volgina, Darya, Pascual-Pasto, Guillem, Rodriguez-Garcia, Alba, Uzun, Yasin, Arsenian-Henriksson, Marie, Powell, Daniel J., Bosse, Kristopher R., Kossenkov, Andrew, Tan, Kai, Hogarty, Michael D., Maris, John M., and Dang, Chi V.

Published
2022

5. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.

Author

Twist, Clare J, Schmidt, Mary Lou, Naranjo, Arlene, London, Wendy B, Tenney, Sheena C, Marachelian, Araz, Shimada, Hiroyuki, Collins, Margaret H, Esiashvili, Natia, Adkins, E Stanton, Mattei, Peter, Handler, Michael, Katzenstein, Howard, Attiyeh, Edward, Hogarty, Michael D, Gastier-Foster, Julie, Wagner, Elizabeth, Matthay, Katherine K, Park, Julie R, Maris, John M, and Cohn, Susan L

Subjects
Cancer, Rare Diseases, Pediatric Cancer, Neuroblastoma, Clinical Research, Neurosciences, Pediatric, Age Factors, Algorithms, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Clinical Decision-Making, Decision Support Techniques, Drug Administration Schedule, Female, Humans, Infant, Infant, Newborn, Male, Neoadjuvant Therapy, Neoplasm Staging, Progression-Free Survival, Prospective Studies, Risk Assessment, Risk Factors, Time Factors, United States, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe primary objective of the Children's Oncology Group study ANBL0531 (ClinicalTrials.gov identifier: NCT00499616) was to reduce therapy for subsets of patients with intermediate-risk neuroblastoma using a biology- and response-based algorithm to assign treatment duration while maintaining a 3-year overall survival (OS) of 95% or more for the entire cohort.Patients and methodsChildren younger than age 12 years with intermediate-risk stage 2A/2B or stage 3 tumors with favorable histology; infants younger than age 365 days with stage 3, 4 or 4S disease; and toddlers from 365 to younger than 547 days with favorable histology, hyperdiploid stage 4, or unfavorable histology stage 3 tumors were eligible. Patients with MYCN-amplified tumors were excluded. Patients were assigned to initially receive two (group 2), four (group 3), or eight (group 4) cycles of chemotherapy with or without surgery on the basis of prognostic markers, including allelic status of chromosomes 1p and 11q; ultimate duration of therapy was determined by overall response.ResultsBetween 2007 and 2011, 404 evaluable patients were enrolled. Compared with legacy Children's Oncology Group studies, subsets of patients had a reduction in treatment. The 3-year event-free survival and OS rates were 83.2% (95% CI, 79.4% to 87.0%) and 94.9% (95% CI, 92.7% to 97.2%), respectively. Infants with stage 4 tumors with favorable biology (n = 61) had superior 3-year event-free survival compared with patients with one or more unfavorable biologic features (n = 47; 86.9% [95% CI, 78.3% to 95.4%] v 66.8% [95% CI, 53.1% to 80.6%]; P = .02), with a trend toward OS advantage (95.0% [95% CI, 89.5% to 100%] v 86.7% [95% CI, 76.6% to 96.7%], respectively; P = .08). OS for patients with localized disease was 100%.ConclusionExcellent survival was achieved with this treatment algorithm, with reduction of therapy for subsets of patients. More-effective treatment strategies still are needed for infants with unfavorable biology stage 4 disease.

Published
2019

6. Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531.

Author

Voeller, Julie, Katzenstein, Howard M., Naranjo, Arlene, Tenney, Sheena C., Chen, Lulu, London, Wendy B., Handler, Michael H., Schmidt, Mary Lou, Shimada, Hiroyuki, Hogarty, Michael D., Gastier‐Foster, Julie, Park, Julie R., Cohn, Susan L., Maris, John M., Bagatell, Rochelle, and Twist, Clare J.

Published
2025
Full Text
View/download PDF

8. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

Author

Erbe, Amy K, Wang, Wei, Carmichael, Lakeesha, Kim, KyungMann, Mendonça, Eneida A, Song, Yiqiang, Hess, Dustin, Reville, Patrick K, London, Wendy B, Naranjo, Arlene, Hank, Jacquelyn A, Diccianni, Mitchell B, Reisfeld, Ralph A, Gillies, Stephen D, Matthay, Katherine K, Cohn, Susan L, Hogarty, Michael D, Maris, John M, Park, Julie R, Ozkaynak, M Fevzi, Gilman, Andrew L, Yu, Alice L, and Sondel, Paul M

Subjects
Neurosciences, Immunization, Pediatric, Cancer, Rare Diseases, Pediatric Research Initiative, Clinical Trials and Supportive Activities, Neuroblastoma, Genetics, Clinical Research, Pediatric Cancer, Vaccine Related, Antibodies, Monoclonal, Antineoplastic Agents, Immunological, Cell Line, Tumor, Clinical Trials, Phase III as Topic, Female, Genotype, Humans, Immunotherapy, Ligands, Male, Receptors, KIR, Receptors, KIR2DL1, Receptors, KIR3DL1, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose: In 2010, a Children's Oncology Group (COG) phase III randomized trial for patients with high-risk neuroblastoma (ANBL0032) demonstrated improved event-free survival (EFS) and overall survival (OS) following treatment with an immunotherapy regimen of dinutuximab, GM-CSF, IL2, and isotretinoin compared with treatment with isotretinoin alone. Dinutuximab, a chimeric anti-GD2 monoclonal antibody, acts in part via natural killer (NK) cells. Killer immunoglobulin-like receptors (KIR) on NK cells and their interactions with KIR-ligands can influence NK cell function. We investigated whether KIR/KIR-ligand genotypes were associated with EFS or OS in this trial.Experimental Design: We genotyped patients from COG study ANBL0032 and evaluated the effect of KIR/KIR-ligand genotypes on clinical outcomes. Cox regression models and log-rank tests were used to evaluate associations of EFS and OS with KIR/KIR-ligand genotypes.Results: In this trial, patients with the "all KIR-ligands present" genotype as well as patients with inhibitory KIR2DL2 with its ligand (HLA-C1) together with inhibitory KIR3DL1 with its ligand (HLA-Bw4) were associated with improved outcome if they received immunotherapy. In contrast, for patients with the complementary KIR/KIR-ligand genotypes, clinical outcome was not significantly different for patients who received immunotherapy versus those receiving isotretinoin alone.Conclusions: These data show that administration of immunotherapy is associated with improved outcome for neuroblastoma patients with certain KIR/KIR-ligand genotypes, although this was not seen for patients with other KIR/KIR-ligand genotypes. Further investigation of KIR/KIR-ligand genotypes may clarify their role in cancer immunotherapy and may enable KIR/KIR-ligand genotyping to be used prospectively for identifying patients likely to benefit from certain cancer immunotherapy regimens. Clin Cancer Res; 24(1); 189-96. ©2017 AACRSee related commentary by Cheung and Hsu, p. 3.

Published
2018

9. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

Author

Moreno, Lucas, Barone, Giuseppe, DuBois, Steven G., Molenaar, Jan, Fischer, Matthias, Schulte, Johannes, Eggert, Angelika, Schleiermacher, Gudrun, Speleman, Frank, Chesler, Louis, Geoerger, Birgit, Hogarty, Michael D., Irwin, Meredith S., Bird, Nick, Blanchard, Guy B., Buckland, Sean, Caron, Hubert, Davis, Susan, De Wilde, Bram, Deubzer, Hedwig E., Dolman, Emmy, Eilers, Martin, George, Rani E., George, Sally, Jaroslav, Štěrba, Maris, John M., Marshall, Lynley, Merchant, Melinda, Mortimer, Peter, Owens, Cormac, Philpott, Anna, Poon, Evon, Shay, Jerry W., Tonelli, Roberto, Valteau-Couanet, Dominique, Vassal, Gilles, Park, Julie R., and Pearson, Andrew D.J.

Published
2020
Full Text
View/download PDF

10. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy

Author

Erbe, Amy K, Wang, Wei, Reville, Patrick K, Carmichael, Lakeesha, Kim, KyungMann, Mendonca, Eneida A, Song, Yiqiang, Hank, Jacquelyn A, London, Wendy B, Naranjo, Arlene, Hong, Fangxin, Hogarty, Michael D, Maris, John M, Park, Julie R, Ozkaynak, MF, Miller, Jeffrey S, Gilman, Andrew L, Kahl, Brad, Yu, Alice L, and Sondel, Paul M

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Immunology, Clinical Trials and Supportive Activities, Immunization, Rare Diseases, Cancer, Hematology, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, KIR, KIR-ligand, HLA-Bw4, HLA, MHC class I, natural killer cells, cancer immunotherapy, Medical Microbiology, Biochemistry and cell biology, Genetics
Abstract

Killer-cell immunoglobulin-like receptors (KIRs) are a family of glycoproteins expressed primarily on natural killer cells that can regulate their function. Inhibitory KIRs recognize MHC class I molecules (KIR-ligands) as ligands. We have reported associations of KIRs and KIR-ligands for patients in two monoclonal antibody (mAb)-based trials: (1) A Children's Oncology Group (COG) trial for children with high-risk neuroblastoma randomized to immunotherapy treatment with dinutuximab (anti-GD2 mAb) + GM-CSF + IL-2 + isotretinion or to treatment with isotretinoin alone and (2) An Eastern Cooperative Oncology Group (ECOG) trial for adults with low-tumor burden follicular lymphoma responding to an induction course of rituximab (anti-CD20 mAb) and randomized to treatment with maintenance rituximab or no-maintenance rituximab. In each trial, certain KIR/KIR-ligand genotypes were associated with clinical benefit for patients randomized to immunotherapy treatment (immunotherapy in COG; maintenance rituximab in ECOG) as compared to patients that did not receive the immunotherapy [isotretinoin alone (COG); no-maintenance (ECOG)]. Namely, patients with both KIR3DL1 and its HLA-Bw4 ligand (KIR3DL1+/HLA-Bw4+ genotype) had improved clinical outcomes if randomized to immunotherapy regimens, as compared to patients with the KIR3DL1+/HLA-Bw4+ genotype randomized to the non-immunotherapy regimen. Conversely, patients that did not have the KIR3DL1+/HLA-Bw4+ genotype showed no evidence of a difference in outcome if receiving the immunotherapy vs. no-immunotherapy. For each trial, HLA-Bw4 status was determined by assessing the genotypes of three separate isoforms of HLA-Bw4: (1) HLA-B-Bw4 with threonine at amino acid 80 (B-Bw4-T80); (2) HLA-B-Bw4 with isoleucine at amino acid 80 (HLA-B-Bw4-I80); and (3) HLA-A with a Bw4 epitope (HLA-A-Bw4). Here, we report on associations with clinical outcome for patients with KIR3DL1 and these separate isoforms of HLA-Bw4. Patients randomized to immunotherapy with KIR3DL1+/A-Bw4+ or with KIR3DL1+/B-Bw4-T80+ had better outcome vs. those randomized to no-immunotherapy, whereas for those with KIR3DL1+/B-Bw4-I80+ there was no evidence of a difference based on immunotherapy vs. no-immunotherapy. Additionally, we observed differences within treatment types (either within immunotherapy or no-immunotherapy) that were associated with the genotype status for the different KIR3DL1/HLA-Bw4-isoforms. These studies suggest that specific HLA-Bw4 isoforms may differentially influence response to these mAb-based immunotherapy, further confirming the involvement of KIR-bearing cells in tumor-reactive mAb-based cancer immunotherapy.

Published
2017

11. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis

Author

Parekh, Deevyashali, primary, Lin, Howard, additional, Batajoo, Akanksha, additional, Peckham‐Gregory, Erin, additional, Karri, Vivekanudeep, additional, Stanton, Whitney, additional, Scull, Brooks, additional, Fleishmann, Ryan, additional, El‐Mallawany, Nader, additional, Eckstein, Olive S., additional, Prudowsky, Zachary D., additional, Gulati, Nitya, additional, Agrusa, Jennifer E., additional, Ahmed, Asra Z., additional, Chu, Roland, additional, Dietz, Matthew S., additional, Goldman, Stanton C., additional, Hogarty, Michael D., additional, Imran, Hamayun, additional, Intzes, Stefanos, additional, Kim, Jenny M., additional, Kopp, Lisa M., additional, Levy, Carolyn Fein, additional, Neff, Philip, additional, Pillai, Pallavi M., additional, Sisk, Bryan A., additional, Schiff, Deborah E., additional, Trobaugh‐Lotrario, Angela D., additional, Walkovich, Kelly, additional, McClain, Kenneth L., additional, and Allen, Carl E., additional

Published
2024
Full Text
View/download PDF

13. Fixing the leaky pipeline: identifying solutions for improving pediatrician-scientist training during pediatric residency

Author

Burns, Audrea M., Ackerman, Kate G., Thammasitboon, Satid, Rassbach, Caroline E., Ward, Mark A., Blankenburg, Rebecca L., Forster, Catherine S., McPhillips, Heather A., Wenger, Tara L., Powell, Weston T., Heyman, Melvin B., Hogarty, Michael D., Boyer, Debra, Hostetter, Margaret, Weiss, Pnina, Nguyen, Suong T., Parsons, Donald Williams, Moore, Daniel J., Byrne, Bobbi J., French, Anthony R., and Orange, Jordan S.

Published
2020
Full Text
View/download PDF

16. Reprogramming neuroblastoma by diet-enhanced polyamine depletion

Author

Cherkaoui, Sarah, primary, Yang, Lifeng, additional, McBride, Matthew J, additional, Turn, Christina, additional, Lu, Wenyun, additional, Eigenmann, Caroline, additional, Allen, George E, additional, Panasenko, Olesya O, additional, Zhang, Lu, additional, Vu, Annette, additional, Liu, Kangning, additional, Li, Yimei, additional, Gandhi, Om H, additional, Surrey, Lea, additional, Wierer, Michael, additional, White, Eileen, additional, Rabinowitz, Joshua D, additional, Hogarty, Michael D, additional, and Morscher, Raphael J, additional

Published
2024
Full Text
View/download PDF

17. TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer

Author

Witwicki, Robert M., Ekram, Muhammad B., Qiu, Xintao, Janiszewska, Michalina, Shu, Shaokun, Kwon, Mijung, Trinh, Anne, Frias, Elizabeth, Ramadan, Nadire, Hoffman, Greg, Yu, Kristine, Xie, Yingtian, McAllister, Gregory, McDonald, Rob, Golji, Javad, Schlabach, Michael, deWeck, Antoine, Keen, Nicholas, Chan, Ho Man, Ruddy, David, Rejtar, Tomas, Sovath, Sosathya, Silver, Serena, Sellers, William R., Jagani, Zainab, Hogarty, Michael D., Roberts, Charles, Brown, Myles, Stegmaier, Kimberly, Long, Henry, Shivdasani, Ramesh A., Pellman, David, and Polyak, Kornelia

Published
2018
Full Text
View/download PDF

18. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group

Author

DuBois, Steven G, Geier, Ethan, Batra, Vandana, Yee, Sook Wah, Neuhaus, John, Segal, Mark, Martinez, Daniel, Pawel, Bruce, Yanik, Greg, Naranjo, Arlene, London, Wendy B, Kreissman, Susan, Baker, David, Attiyeh, Edward, Hogarty, Michael D, Maris, John M, Giacomini, Kathleen, and Matthay, Katherine K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Cancer, Neuroblastoma, Genetics, Pediatric Cancer, Pediatric, Neurosciences
Abstract

Purpose. (123)I-metaiodobenzylguanidine (MIBG) is used for the diagnostic evaluation of neuroblastoma. We evaluated the relationship between norepinephrine transporter (NET) expression and clinical MIBG uptake. Methods. Quantitative reverse transcription PCR (N = 82) and immunohistochemistry (IHC; N = 61) were performed for neuroblastoma NET mRNA and protein expression and correlated with MIBG avidity on diagnostic scans. The correlation of NET expression with clinical features was also performed. Results. Median NET mRNA expression level for the 19 MIBG avid patients was 12.9% (range 1.6-73.7%) versus 5.9% (range 0.6-110.0%) for the 8 nonavid patients (P = 0.31). Median percent NET protein expression was 50% (range 0-100%) in MIBG avid patients compared to 10% (range 0-80%) in nonavid patients (P = 0.027). MYCN amplified tumors had lower NET protein expression compared to nonamplified tumors (10% versus 50%; P = 0.0002). Conclusions. NET protein expression in neuroblastoma correlates with MIBG avidity. MYCN amplified tumors have lower NET protein expression.

Published
2012

20. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations

Author

Brady, Samuel W., Liu, Yanling, Ma, Xiaotu, Gout, Alexander M., Hagiwara, Kohei, Zhou, Xin, Wang, Jian, Macias, Michael, Chen, Xiaolong, Easton, John, Mulder, Heather L., Rusch, Michael, Wang, Lu, Nakitandwe, Joy, Lei, Shaohua, Davis, Eric M., Naranjo, Arlene, Cheng, Cheng, Maris, John M., Downing, James R., Cheung, Nai-Kong V., Hogarty, Michael D., Dyer, Michael A., and Zhang, Jinghui

Published
2020
Full Text
View/download PDF

21. MYCN amplification and ATRX mutations are incompatible in neuroblastoma

Author

Zeineldin, Maged, Federico, Sara, Chen, Xiang, Fan, Yiping, Xu, Beisi, Stewart, Elizabeth, Zhou, Xin, Jeon, Jongrye, Griffiths, Lyra, Nguyen, Rosa, Norrie, Jackie, Easton, John, Mulder, Heather, Yergeau, Donald, Liu, Yanling, Wu, Jianrong, Van Ryn, Collin, Naranjo, Arlene, Hogarty, Michael D., Kamiński, Marcin M., Valentine, Marc, Pruett-Miller, Shondra M., Pappo, Alberto, Zhang, Jinghui, Clay, Michael R., Bahrami, Armita, Vogel, Peter, Lee, Seungjae, Shelat, Anang, Sarthy, Jay F., Meers, Michael P., George, Rani E., Mardis, Elaine R., Wilson, Richard K., Henikoff, Steven, Downing, James R., and Dyer, Michael A.

Published
2020
Full Text
View/download PDF

22. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1

Author

Granger, M. Meaghan, Naranjo, Arlene, Bagatell, Rochelle, DuBois, Steven G., McCune, Jeannine S., Tenney, Sheena C., Weiss, Brian D., Mosse, Yael P., Asgharzadeh, Shahab, Grupp, Stephen A., Hogarty, Michael D., Gastier-Foster, Julie M., Mills, Denise, Shulkin, Barry L., Parisi, Marguerite T., London, Wendy B., Han-Chang, John, Panoff, Joseph, von Allmen, Daniel, Jarzembowski, Jason A., Park, Julie R., and Yanik, Gregory A.

Published
2021
Full Text
View/download PDF

23. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification

Author

Bender, Hannah G., primary, Irwin, Meredith S., additional, Hogarty, Michael D., additional, Castleberry, Robert, additional, Maris, John M., additional, Kao, Pei-Chi, additional, Zhang, Fan F., additional, Naranjo, Arlene, additional, Cohn, Susan L., additional, and London, Wendy B., additional

Published
2023
Full Text
View/download PDF

24. Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

Author

Pinto, Navin, primary, Naranjo, Arlene, primary, Ding, Xiangming, primary, Zhang, Fan F., primary, Hibbitts, Emily, primary, Kennedy, Rebekah, primary, Tibbetts, Rachelle, primary, Wong-Michalak, Shannon, primary, Craig, David W., primary, Manojlovic, Zarko, primary, Hogarty, Michael D., primary, Kreissman, Susan, primary, Bagatell, Rochelle, primary, Irwin, Meredith S., primary, Park, Julie R., primary, and Asgharzadeh, Shahab, primary

Published
2023
Full Text
View/download PDF

25. Data from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

Author

Pinto, Navin, primary, Naranjo, Arlene, primary, Ding, Xiangming, primary, Zhang, Fan F., primary, Hibbitts, Emily, primary, Kennedy, Rebekah, primary, Tibbetts, Rachelle, primary, Wong-Michalak, Shannon, primary, Craig, David W., primary, Manojlovic, Zarko, primary, Hogarty, Michael D., primary, Kreissman, Susan, primary, Bagatell, Rochelle, primary, Irwin, Meredith S., primary, Park, Julie R., primary, and Asgharzadeh, Shahab, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

Author

Pinto, Navin, primary, Naranjo, Arlene, primary, Ding, Xiangming, primary, Zhang, Fan F., primary, Hibbitts, Emily, primary, Kennedy, Rebekah, primary, Tibbetts, Rachelle, primary, Wong-Michalak, Shannon, primary, Craig, David W., primary, Manojlovic, Zarko, primary, Hogarty, Michael D., primary, Kreissman, Susan, primary, Bagatell, Rochelle, primary, Irwin, Meredith S., primary, Park, Julie R., primary, and Asgharzadeh, Shahab, primary

Published
2023
Full Text
View/download PDF

27. Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

Author

Pinto, Navin, primary, Naranjo, Arlene, primary, Ding, Xiangming, primary, Zhang, Fan F., primary, Hibbitts, Emily, primary, Kennedy, Rebekah, primary, Tibbetts, Rachelle, primary, Wong-Michalak, Shannon, primary, Craig, David W., primary, Manojlovic, Zarko, primary, Hogarty, Michael D., primary, Kreissman, Susan, primary, Bagatell, Rochelle, primary, Irwin, Meredith S., primary, Park, Julie R., primary, and Asgharzadeh, Shahab, primary

Published
2023
Full Text
View/download PDF

28. SUPPLEMENTAL MATERIALS from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

Author

Erbe, Amy K., primary, Wang, Wei, primary, Carmichael, Lakeesha, primary, Kim, KyungMann, primary, Mendonça, Eneida A., primary, Song, Yiqiang, primary, Hess, Dustin, primary, Reville, Patrick K., primary, London, Wendy B., primary, Naranjo, Arlene, primary, Hank, Jacquelyn A., primary, Diccianni, Mitchell B., primary, Reisfeld, Ralph A., primary, Gillies, Stephen D., primary, Matthay, Katherine K., primary, Cohn, Susan L., primary, Hogarty, Michael D., primary, Maris, John M., primary, Park, Julie R., primary, Ozkaynak, M. Fevzi, primary, Gilman, Andrew L., primary, Yu, Alice L., primary, and Sondel, Paul M., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Data (for publication) from Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression

Author

Evageliou, Nicholas F., primary, Haber, Michelle, primary, Vu, Annette, primary, Laetsch, Theodore W., primary, Murray, Jayne, primary, Gamble, Laura D., primary, Cheng, Ngan Ching, primary, Liu, Kangning, primary, Reese, Megan, primary, Corrigan, Kelly A., primary, Ziegler, David S., primary, Webber, Hannah, primary, Hayes, Candice S., primary, Pawel, Bruce, primary, Marshall, Glenn M., primary, Zhao, Huaqing, primary, Gilmour, Susan K., primary, Norris, Murray D., primary, and Hogarty, Michael D., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 1, Tables 1-3 from miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples

Author

De Preter, Katleen, primary, Mestdagh, Pieter, primary, Vermeulen, Joëlle, primary, Zeka, Fjoralba, primary, Naranjo, Arlene, primary, Bray, Isabella, primary, Castel, Victoria, primary, Chen, Caifu, primary, Drozynska, Elzbieta, primary, Eggert, Angelika, primary, Hogarty, Michael D., primary, Iżycka-Swieszewska, Ewa, primary, London, Wendy B., primary, Noguera, Rosa, primary, Piqueras, Marta, primary, Bryan, Kenneth, primary, Schowe, Benjamin, primary, van Sluis, Peter, primary, Molenaar, Jan J., primary, Schramm, Alexander, primary, Schulte, Johannes H., primary, Stallings, Raymond L., primary, Versteeg, Rogier, primary, Laureys, Geneviève, primary, Van Roy, Nadine, primary, Speleman, Frank, primary, and Vandesompele, Jo, primary

Published
2023
Full Text
View/download PDF

31. Table S3 from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

Author

Erbe, Amy K., primary, Wang, Wei, primary, Carmichael, Lakeesha, primary, Kim, KyungMann, primary, Mendonça, Eneida A., primary, Song, Yiqiang, primary, Hess, Dustin, primary, Reville, Patrick K., primary, London, Wendy B., primary, Naranjo, Arlene, primary, Hank, Jacquelyn A., primary, Diccianni, Mitchell B., primary, Reisfeld, Ralph A., primary, Gillies, Stephen D., primary, Matthay, Katherine K., primary, Cohn, Susan L., primary, Hogarty, Michael D., primary, Maris, John M., primary, Park, Julie R., primary, Ozkaynak, M. Fevzi, primary, Gilman, Andrew L., primary, Yu, Alice L., primary, and Sondel, Paul M., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure Legends 1-3 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Author

Hogarty, Michael D., primary, Norris, Murray D., primary, Davis, Kimberly, primary, Liu, Xueyuan, primary, Evageliou, Nicholas F., primary, Hayes, Candace S., primary, Pawel, Bruce, primary, Guo, Rong, primary, Zhao, Huaqing, primary, Sekyere, Eric, primary, Keating, Joanna, primary, Thomas, Wayne, primary, Cheng, Ngan Ching, primary, Murray, Jayne, primary, Smith, Janice, primary, Sutton, Rosemary, primary, Venn, Nicola, primary, London, Wendy B., primary, Buxton, Allen, primary, Gilmour, Susan K., primary, Marshall, Glenn M., primary, and Haber, Michelle, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 1 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Author

Hogarty, Michael D., primary, Norris, Murray D., primary, Davis, Kimberly, primary, Liu, Xueyuan, primary, Evageliou, Nicholas F., primary, Hayes, Candace S., primary, Pawel, Bruce, primary, Guo, Rong, primary, Zhao, Huaqing, primary, Sekyere, Eric, primary, Keating, Joanna, primary, Thomas, Wayne, primary, Cheng, Ngan Ching, primary, Murray, Jayne, primary, Smith, Janice, primary, Sutton, Rosemary, primary, Venn, Nicola, primary, London, Wendy B., primary, Buxton, Allen, primary, Gilmour, Susan K., primary, Marshall, Glenn M., primary, and Haber, Michelle, primary

Published
2023
Full Text
View/download PDF

36. Data from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Author

Hogarty, Michael D., primary, Norris, Murray D., primary, Davis, Kimberly, primary, Liu, Xueyuan, primary, Evageliou, Nicholas F., primary, Hayes, Candace S., primary, Pawel, Bruce, primary, Guo, Rong, primary, Zhao, Huaqing, primary, Sekyere, Eric, primary, Keating, Joanna, primary, Thomas, Wayne, primary, Cheng, Ngan Ching, primary, Murray, Jayne, primary, Smith, Janice, primary, Sutton, Rosemary, primary, Venn, Nicola, primary, London, Wendy B., primary, Buxton, Allen, primary, Gilmour, Susan K., primary, Marshall, Glenn M., primary, and Haber, Michelle, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 3 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Author

Hogarty, Michael D., primary, Norris, Murray D., primary, Davis, Kimberly, primary, Liu, Xueyuan, primary, Evageliou, Nicholas F., primary, Hayes, Candace S., primary, Pawel, Bruce, primary, Guo, Rong, primary, Zhao, Huaqing, primary, Sekyere, Eric, primary, Keating, Joanna, primary, Thomas, Wayne, primary, Cheng, Ngan Ching, primary, Murray, Jayne, primary, Smith, Janice, primary, Sutton, Rosemary, primary, Venn, Nicola, primary, London, Wendy B., primary, Buxton, Allen, primary, Gilmour, Susan K., primary, Marshall, Glenn M., primary, and Haber, Michelle, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 2 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Author

Hogarty, Michael D., primary, Norris, Murray D., primary, Davis, Kimberly, primary, Liu, Xueyuan, primary, Evageliou, Nicholas F., primary, Hayes, Candace S., primary, Pawel, Bruce, primary, Guo, Rong, primary, Zhao, Huaqing, primary, Sekyere, Eric, primary, Keating, Joanna, primary, Thomas, Wayne, primary, Cheng, Ngan Ching, primary, Murray, Jayne, primary, Smith, Janice, primary, Sutton, Rosemary, primary, Venn, Nicola, primary, London, Wendy B., primary, Buxton, Allen, primary, Gilmour, Susan K., primary, Marshall, Glenn M., primary, and Haber, Michelle, primary

Published
2023
Full Text
View/download PDF

43. Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

Author

Pinto, Navin, primary, Naranjo, Arlene, additional, Ding, Xiangming, additional, Zhang, Fan F., additional, Hibbitts, Emily, additional, Kennedy, Rebekah, additional, Tibbetts, Rachelle, additional, Wong-Michalak, Shannon, additional, Craig, David W., additional, Manojlovic, Zarko, additional, Hogarty, Michael D., additional, Kreissman, Susan, additional, Bagatell, Rochelle, additional, Irwin, Meredith S., additional, Park, Julie R., additional, and Asgharzadeh, Shahab, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results